Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma

Published:2006-01 Issue:9 Volume:47 Page:1818-1821
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Pro Barbara,Hagemeister Fredrick B.,McLaughlin Peter,Romaguera Jorge,Rodriguez Maria A.,Cabanillas Fernando,Tiongson Lili paz,Younes Anas

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190600684999

Reference9 articles.

1. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.

2. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study.

3. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

4. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma

5. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An overview on anti-tubulin agents for the treatment of lymphoma patients;Pharmacology & Therapeutics;2020-07

2. Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study;Leukemia & Lymphoma;2017-06-09

3. Alternol, a natural compound, exerts an anti‐tumour effect on osteosarcoma by modulating of STAT 3 and ROS / MAPK signalling pathways;Journal of Cellular and Molecular Medicine;2016-09-14

4. Current Awareness in Hematological Oncology;Hematological Oncology;2007

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3